Prostate Cancer

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

As Susan Sullivan discussed her lung cancer diagnosis and the FDA discusses banning specific hair straightening products due to long-term health effects, here’s what’s happening in the oncology space this week.

Rashid K. Sayyid, MD, MSc, gives a brief overview of treatment options for nonmetastatic castrate-resistant prostate cancer.

Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer.

An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer.

A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer.

Adding BXCL701 to Keytruda tended to improve overall survival outcomes for patients with small cell neuroendocrine prostate cancer, according to phase 2 study results.

As Len Goodman’s cause of death was announced and LSU defenseman Greg Brooks announces rare form of brain cancer, here is what’s happening in the oncology space this week.

A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.

Expert perspectives on how clinical trials and real-world evidence contribute to treatment decisions in prostate cancer.

I knew virtually nothing about cancer until I became a caregiver for my aunt Carolyn, who died of colorectal cancer in 2000.

A genitourinary oncologist provides insights on the treatment decision-making process and the roles of guidelines for prostate cancer.

An experienced public health and cancer researcher offers advice to patients newly diagnosed with prostate cancer and discusses barriers to access to care.

Rashid K. Sayyid, MD, MSc, describes the staging and risk stratification process for patients with prostate cancer and their effect on prognosis.

Reginald Tucker-Seeley, MA, ScM, ScD, gives an overview of the screening and diagnosis process of prostate cancer.

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed.

In honor of Prostate Cancer Awareness Month, we looked back at some of our most viewed and significant prostate cancer content from the summer of 2023.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer.

When asked for recommended treatments for certain types of cancer, ChatGPT missed the mark about one-third of the time, research showed.

Clinical insights on the typical presentation of prostate cancer and how the disease is diagnosed.

Alicia Morgans, MD, MPH, reviews the incidence of prostate cancer and risk factors associated with the disease.

Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer.

New PSMA PET/CT can detect signs of prostate cancer within elderly patients without the need of a biopsy.